WilmerHale Represents Underwriters in $258.75M Public Offering of Kymera Therapeutics

WilmerHale Represents Underwriters in $258.75M Public Offering of Kymera Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 2,830,533 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 828,220 additional shares of common stock, and pre-funded warrants to purchase 3,519,159 shares of common stock by Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera received approximately $258.75 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on August 19, 2024 and closed on August 21, 2024.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer, Matt Kosior and Michaela Rosen with assistance from Barish Ozdamar on intellectual property matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel